newsfilter
← Latest News
GlobeNewswire·

Harpoon Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial at 2022 ASCO Annual Meeting

Clinically active and well tolerated in patients with solid tumors Favorable safety profile emerging: 22% of patients experienced Grade 1-2 cytokine release syndrome (CRS); no Grade 3 or higher CRS One confirmed partial response; 27% of small cell lun